Clinical Trials
11
Trial Phases
3 Phases
Drug Approvals
3
Drug Approvals
Paclitaxel Oral Solution
- Product Name
- 紫杉醇口服溶液
- Approval Number
- 国药准字HJ20240098
- Approval Date
- Sep 19, 2024
Paclitaxel Oral Solution
- Product Name
- 紫杉醇口服溶液
- Approval Number
- 国药准字HJ20240096
- Approval Date
- Sep 19, 2024
Paclitaxel Oral Solution
- Product Name
- 紫杉醇口服溶液
- Approval Number
- 国药准字HJ20240097
- Approval Date
- Sep 19, 2024
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
A Phase 1 Clinical Trial DHP2306R1 and DHP2306R2 in Healthy Adult Volunteers
- First Posted Date
- 2024-05-02
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Daehwa Pharmaceutical Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT06395155
- Locations
- 🇰🇷
Chungbuk National University Hospital, Chungbuk, Korea, Republic of
Phase 1 Study of DHP2302R1 and DHP2302R2 in Healthy Adult Volunteers
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Daehwa Pharmaceutical Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT06318845
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Gwanak-gu, Korea, Republic of
Food Effect on Pharmacokinetics and Safety of DHP107 (Liporaxel®) FEEL Study
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: DHP107(Oral paclitaxel)
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Daehwa Pharmaceutical Co., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT04675528
- Locations
- 🇭🇺
University of Semmelweis, 1st Internal Medicine Clinic, Department of Clinical Pharmacology, Budapest, Hungary
🇭🇺National Institute of Oncology, Budapest, Hungary
🇭🇺University of Debrecen-Clinical Center, Internal Medicine Clinic, Department of Clinical Pharmacology, Debrecen, Hungary
Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer
- Conditions
- Recurrent or Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2017-10-30
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Daehwa Pharmaceutical Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT03326102
- Locations
- 🇺🇸
California Research Institute (CRI), Los Angeles, California, United States
🇺🇸University of California San Francisco (UCSF), San Francisco, California, United States
🇺🇸Boca Raton Regional Hospital (BRRH), Boca Raton, Florida, United States
Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy
- Conditions
- Recurrent or Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Daehwa Pharmaceutical Co., Ltd.
- Target Recruit Count
- 549
- Registration Number
- NCT03315364
- Locations
- 🇧🇬
Oncology Complex Center - Burgas'' Ltd., Medical Oncology Department, Burgas, Bulgaria
🇧🇬Multi-profile Hospital for Active Treatment Uni Hospital Ltd. Medical Oncology Department, Panagyurishte, Bulgaria
🇧🇬Medical Center Nadezhda Clinical" Ltd.,, Sofia, Bulgaria
- Prev
- 1
- 2
- Next